America v. Secretary of Health and Human Services
Opinion
In the United States Court of Federal Claims OFFICE OF SPECIAL MASTERS No. 17-542V
(not to be published)
************************* Chief Special Master Corcoran
*
ASHLEY AMERICA , * * Filed: June 7, 2022 Petitioner, *
v. *
*
SECRETARY OF HEALTH * AND HUMAN SERVICES, *
*
Respondent. *
*
*************************
Renee J. Gentry, Vaccine Injury Clinic, George Washington Univ. Law School, Washington, DC, for Petitioner.
Amanda Pasciuto, U.S. Dep’t of Justice, Washington, DC, for Respondent.
DECISION GRANTING ATTORNEY’S FEES AND COSTS 1
On April 17, 2017, Maria and Rui America, on behalf of their then-minor child, Ashley, filed a Petition under the National Vaccine Injury Compensation Program (the “Vaccine Program”), 2 alleging that as a result of receiving the human papillomavirus (“HPV”) and influenza (“flu”) vaccines, Ashley developed neurocardiogenic syncope (“NCS”). Petition (ECF No. 1) at 1–2. Ms. America became the named petitioner after she turned 18 years old. ECF No. 8. She
1 Although I have not formally designated this Decision for publication, it will nevertheless be posted on the United States Court of Federal Claims website, in accordance with the E-Government Act of 2002, 44 U.S.C. § 3501 (2012). As provided by 42 U.S.C. § 300aa-12(d)(4)(B), however, the parties may object to the Decision’s inclusion of certain kinds of confidential information. Specifically, under Vaccine Rule 18(b), each party has fourteen days within which to request redaction “of any information furnished by that party: (1) that is a trade secret or commercial or financial in substance and is privileged or confidential; or (2) that includes medical files or similar files, the disclosure of which would constitute a clearly unwarranted invasion of privacy.” Vaccine Rule 18(b). Otherwise, the whole Decision will be available to the public. Id. 2 The Vaccine Program comprises Part 2 of the National Childhood Vaccine Injury Act of 1986, Pub. L. No. 99-660, 100 Stat. 3755 (codified as amended at 42 U.S.C. §§ 300aa-10–34 (2012)) (hereinafter “Vaccine Act” or “the Act”). All subsequent references to sections of the Vaccine Act shall be to the pertinent subparagraph of 42 U.S.C. § 300aa.
subsequently restricted her claim to alleging only an off-Table significant aggravation claim of her preexisting NCS. ECF No. 55 at 13.
The claim was litigated over several years, and after reviewing the evidence I determined that the matter could be efficiently and fairly resolved by ruling on the record, inviting briefing on the claim from the parties. At the beginning of this year, I issued a decision denying entitlement to compensation. See Decision, dated January 4, 2022. ECF No. 61 (the “Decision”). Petitioner did not opt to appeal my determination.
Petitioner has now filed a motion for a final award of attorney’s fees and costs. Motion, dated May 16, 2022 (ECF No. 65) (“Final Fees Mot.”). Petitioner requests a total of $46,570.79— $12,464.40 to be awarded to the George Washington University Law School Vaccine Injury Litigation Clinic (the “GW Clinic”), $33,706.39 to The Law Firm of Renée J. Gentry, Esq., based on all work performed on the matter by Ms. Gentry, and several other attorneys, and $400.00 to Petitioner for filing fees—for all work performed on the matter since its inception. Id. at 2. The GW Clinic amount is split between fees incurred by admitted attorneys ($4,682.90) and fees based on work performed by law students ($7,781.50). Final Fees Mot. at 1. The sum requested by Ms. Gentry’s firm includes $31,332.50 in fees and $2,373.89 in costs. Id. Respondent reacted to the final fees request on May 31, 2022. Response, dated May 31, 2022 (ECF No. 66) (“Response”). Respondent agrees that Petitioner has satisfied the statutory requirements for attorney’s fees and defers the calculation of the amount to be awarded to my discretion. Id. at 2–3.
For the reasons set forth below, I hereby GRANT Petitioner’s motion, awarding fees and costs in the total amount of $46,578.29.
ANALYSIS
I. Petitioner’s Claim had Reasonable Basis
Although the Vaccine Act only guarantees a reasonable award of attorney’s fees and costs to successful petitioners, a special master may also award fees and costs in an unsuccessful case if: (1) the “petition was brought in good faith”; and (2) “there was a reasonable basis for the claim for which the petition was brought.” Section 15(e)(1). I have in prior decisions set forth at length the criteria to be applied when determining if a claim possessed “reasonable basis” sufficient for a fees award. See, e.g., Sterling v. Sec’y of Health & Hum. Servs., No. 16-551V, 2020 WL 549443, at *4 (Fed. Cl. Spec. Mstr. Jan. 3, 2020). Importantly, establishing reasonable basis does not automatically entitle an unsuccessful claimant to fees, but is instead a threshold obligation; fees can still thereafter be limited, if unreasonable, or even denied entirely.
A claim’s reasonable basis 3 must be demonstrated through some objective evidentiary showing. Cottingham v. Sec’y of Health & Hum. Servs., 971 F.3d 1337, 1344 (Fed. Cir. 2020) (citing Simmons v. Sec’y of Health & Hum. Servs., 875 F.3d 632, 635 (Fed. Cir. 2017)). This objective inquiry is focused on the claim—counsel’s conduct is irrelevant (although it may bulwark good faith). Simmons, 875 F.3d at 635. In addition, reasonable basis inquiries are not static—they evaluate not only what was known at the time the petition was filed, but also take into account what is learned about the evidentiary support for the claim as the matter progresses. Perreira v. Sec’y of Health & Hum. Servs., 33 F.3d 1375, 1377 (Fed. Cir. 1994) (upholding the finding that a reasonable basis for petitioners’ claims ceased to exist once they had reviewed their expert's opinion, which consisted entirely of unsupported speculation). As a result, a claim can “lose” reasonable basis over time.
The standard for finding the existence of reasonable basis is lesser (and thus inherently easier to satisfy) than the preponderant standard applied when assessing entitlement, as cases that fail can still have sufficient objective grounding for a fees award. Braun v. Sec’y of Health & Hum. Servs., 144 Fed. Cl. 72, 77 (2019). The Court of Federal Claims has affirmed that “[r]easonable basis is a standard that petitioners, at least generally, meet by submitting evidence.” Chuisano v. Sec’y of Health & Hum. Servs., 116 Fed. Cl. 276, 287 (Fed. Cl. 2014) (internal quotations omitted) (affirming special master). The factual basis and medical support for the claim is among the evidence that should be considered. Carter v. Sec’y of Health & Hum. Servs., 132 Fed. Cl. 372, 378 (Fed. Cl. 2017). Under the Vaccine Act, special masters have “maximum discretion” in applying the reasonable basis standard. See, e.g., Silva v. Sec’y of Health & Hum. Servs., 108 Fed. Cl. 401, 401–02 (Fed. Cl. 2012). 4
Petitioner’s claim was ultimately unsuccessful, but I find it possessed sufficient objective basis to justify a fees and costs award. Although Petitioner failed to preponderantly establish that she suffered from NCS after receiving the vaccine, her alleged diagnosis was supported by a credentialed expert, and her medical records confirm a history of syncopal episodes. Moreover, although Petitioner failed to demonstrate by a preponderance of the evidence HPV vaccine could aggravate NCS, the theory presented was not wholly lacking in some reliable support. 5
Free access — add to your briefcase to read the full text and ask questions with AI
America v. Secretary of Health and Human Services (America v. Secretary of Health and Human Services) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.